Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Tokyo: 4503, Astellas) and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib , as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia were presented at the 54th Annual Meeting of the American Society of ... (more)

http://www.news-medical.net/news/20121211/Astellas-Ambit-announce-results-from-quizartinib-Phase-2-study-on-acute-myeloid-leukemia.aspx